Current clinical development in multiple myeloma (MM) is showing great promise, with new treatment modalities and several drugs recently approved in quick succession. This high influx of medicines has brought about prescribing and value uncertainty, significant cost pressures on key stakeholders, and a culture of innovation in this specific disease space. Never has it been more necessary to demonstrate product differentiation with real world data (RWD).

Taking into account this current environment, IQVIA is building a research-ready MM real world evidence network in Europe. The network will expedite access to data, insight, and evidence that will facilitate a host of differentiation strategies, including value-based contracting and patient subgroup targeting. IQVIA’s MM network can be used for better evidence generation and eventual market success in this dynamic therapeutic space.

In this paper, discover more about:

• Current MM market dynamics, emerging competition, market access barriers, drivers and constraints
• The European MM data landscape
• How the IQVIA MM network can accelerate study timelines and add scientific credibility
• A recent case study leveraging the IQVIA MM network
• How technology solutions are speeding access to the network and real world insights